AI and 911 stroke detection, iatrogenic Alzheimer's and human growth hormone, seizure dogs and refractory epilepsy
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer's, and seizure dogs for refractory epilepsy.
7 Maalis 20244min
Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.
12 Helmi 20244min
Cerebral amyloid angiopathy and nontraumatic subdural hemorrhage, AI for neurology boards, weight loss drugs and neurologic conditions
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic conditions.
25 Tammi 20244min
Rising incidence of Creutzfeldt-Jakob disease, therapy for prodromal migraine, neurotrauma of blast injury
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the rising incidence of Creutzfeldt-Jakob disease, an effective therapy for prodromal migaine, and neuroinflammation in military personnel exposed to blast injury.
16 Tammi 20244min
DBS and cognition in severe TBI, in utero exposure to antiseizure drugs, best advances of 2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and the editorial board's picks for the best advances of 2023.
2 Tammi 20244min
Parkinson's and suicide risk; biomarkers and underrepresentation in Alzheimer's trials, immune system changes in ALS and Parkinson's.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson's patients; underrepresentation of non-White people in Alzheimer's trial related to biomarker eligibility; early immune systems changes may play early role in ALS and Parkinson's.
21 Joulu 20234min
Serotonin and long COVID, Afib detected 3 years after stroke, Medicare on PET amyloid scans
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare's decision to cover PET amyloid scans means for neurologists.
7 Joulu 20234min
A promising drug for refractory epilepsy; adverse childhood events and headache disorders; pathological engulfment by microglia in dementia.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on a promising potassium channel opener for refractory epilepsy; the impact of adverse childhood events in headache disorders; and excessive engulfment by microglia/astroctyes in dementia.
16 Marras 20234min
